These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 7471120)

  • 1. Phase I trial of PALA.
    Gralla RJ; Casper ES; Natale RB; Yagoda A; Young CW
    Cancer Treat Rep; 1980; 64(12):1301-5. PubMed ID: 7471120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
    Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
    Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
    Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
    J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.
    Hart RD; Ohnuma T; Holland JF
    Cancer Treat Rep; 1980; 64(4-5):617-24. PubMed ID: 6448687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
    Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of combination therapy with PALA and 5-FU.
    Meshad MW; Ervin TJ; Kufe D; Johnson RK; Blum RH; Frei E
    Cancer Treat Rep; 1981; 65(3-4):331-4. PubMed ID: 6263472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of PALA in patients with refractory metastatic sarcomas.
    Kurzrock R; Yap BS; Plager C; Papdopoulos N; Benjamin RS; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1984 Aug; 7(4):305-7. PubMed ID: 6741860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS; Gralla RJ; Kemeny NE
    Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy for colorectal cancer with a combination of PALA and 5-FU.
    Bedikian AY; Stroehlein JR; Karlin DA; Bennetts RW; Bodey GP; Valdivieso M
    Cancer Treat Rep; 1981; 65(9-10):747-53. PubMed ID: 7273010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
    Weiss GR; Ervin TJ; Meshad MW; Schade D; Branfman AR; Bruni RJ; Chadwick M; Kufe DW
    Cancer Chemother Pharmacol; 1982; 8(3):301-4. PubMed ID: 7127661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of continuous-infusion PALA and 5-FU.
    Ardalan B; Jamin D; Jayaram HN; Presant CA
    Cancer Treat Rep; 1984 Mar; 68(3):531-4. PubMed ID: 6231102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotoxicity of the pyrimidine synthesis inhibitor N-phosphonoacetyl-L-aspartate.
    Wiley RG; Gralla RJ; Casper ES; Kemeny N
    Ann Neurol; 1982 Aug; 12(2):175-83. PubMed ID: 7125606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
    Kleeberg UR; Mulder JH; Rümke P; Thomas D; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):723-6. PubMed ID: 6217975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study.
    Muss HB; Slavik M; Bundy B; Stehman FB; Creasman WT
    Am J Clin Oncol; 1984 Jun; 7(3):257-60. PubMed ID: 6731346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of N-(phosphonacetyl)-L-aspartate.
    Erlichman C; Strong JM; Wiernik PH; McAvoy LM; Cohen MH; Levine AS; Hubbard SM; Chabner BA
    Cancer Res; 1979 Oct; 39(10):3992-5. PubMed ID: 157801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of PALA and 5-FU in patients with advanced cancer.
    O'Connell MJ; Powis G; Rubin J; Moertel CG
    Cancer Treat Rep; 1982 Jan; 66(1):77-80. PubMed ID: 7053270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
    Markman M; Chan TC; Cleary S; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(1):80-3. PubMed ID: 3815730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.